| NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS
- News;
DAX:PJT), a bio-therapeutics Company dedicated to the commercialization
of products for a variety of malignant, degenerative and auto-immune
indications, announced today that Dr. Philip J. Schein has joined its
Strategic Business Advisory board, headed by Frank Carlucci. Dr.
Schein, the Founder of US Bioscience, took three new therapies for
cancer and HIV through the development and regulatory approval
processes, and established marketing alliances in the US and throughout
the world. His company was acquired by Medimmune for $450 million in
1995. Medimmune has recently been acquired by AstraZeneca for
approximately $16 Billion. Dr. Schein is the author of over 350 articles
and texts in the fields of clinical cancer research and drug
development. He is the holder of 11 patents and the recipient of
numerous scientific and medical awards. President Clinton appointed Dr.
Schein to the National Cancer Advisory Board. He also served as
President of the American Society of Clinical Oncology, and has chaired
the Food and Drug Administration's Oncologic Drugs Advisory Committee,
where he received the Harvey W. Wiley Medal.
Dr. Schein said, "Pluristem's technology has the potential to be very
beneficial in bone-marrow transplantation, Parkinson's Disease and heart
disease. I want to be part of that."
"We are honored to have Dr. Schein join our board," commented Zami
Aberman, Chairman and CEO, "he has built a significant biotechnology
company before, and his experience will be invaluable to Pluristem as we
execute our ambitious growth plan."
About Pluristem:
Pluristem Life Systems, Inc. is a Company dedicated to the
commercialization of non-personalized (allogeneic) stem cell therapy
products for the treatment of numerous severe degenerative, malignant
and autoimmune disorders. The Company's first planned product, PLX-BMT,
targets a $2 billion market and is intended to resolve the global
shortfall of matched tissue for bone marrow transplantation (BMT) by
improving the engraftment of hematopoietic stem cells (HSCs) contained
in umbilical cord blood (CB). Pluristem's products are derived from
mesenchymal stem cells (MSCs) obtained from the placenta and expanded in
the Company's proprietary PluriX(TM) 3D bioreactor that imitates the
natural microstructure of bone marrow and does not require supplemental
growth factors, cytokines or other exogenous materials. Pluristem
believes the resultant expanded cells, termed PLX cells, are multipotent
and able to differentiate into a variety of cell types as well as being
immune-privileged to protect the recipient from immunological reactions
that often accompanies transplantation. Pluristem believes their future
products will participate in the approximate $30 billion therapeutic and
regenerative cellular market.
Pluristem has offices and is incorporated in the USA with research
and manufacturing facilities in Israel.
www.pluristem.com
Safe Harbor Statement:
This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or current
expectations. Forward-looking statements in this release include that
Pluristem's has the potential to be very beneficial in bone-marrow
transplantation, Parkinson's Disease and heart disease. Factors that
could prevent our forward looking statements from being achieved include
that we may be unable to get regulatory approval for our products; we
may be unsuccessful in developing any products; our technology may not
be validated as we progress further and our methods may not be accepted
by the scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our
process; results in the laboratory may not translate to equally good
results in real surgical settings; our patents may not be sufficient to
protect essential aspects of our technology; competitors may invent
better technology; our products may not work as well as hoped or worse,
our products may harm recipients; and we may not be able to raise funds
for development or working capital when we require it. As well, our
products may never develop into useful products and even if they do,
they may not be approved for sale to the public. For further risk
factors see the Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
|
